[Advances of transforming growth factor-β inhibitors]

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Cell Biology

Background:

• Transforming growth factor-β (TGF-β) is a key cytokine regulating cellular processes like development and wound healing.
• Epithelial-mesenchymal transition (EMT), induced by TGF-β, is critical for tumor invasion and metastasis.
• TGF-β signaling is implicated in various pathologies, including cancer, fibrosis, and scarring.

Purpose of the Study:

• To review recent advancements in the development of novel TGF-β inhibitors.
• To highlight the therapeutic potential of TGF-β inhibitors across diverse medical conditions.
• To provide an overview of the current landscape of TGF-β inhibitor research and clinical applications.

Main Methods:

• Literature review of recent scientific publications and clinical trial data.
• Analysis of studies focusing on novel TGF-β inhibitor mechanisms and therapeutic efficacy.
• Synthesis of information on approved and investigational TGF-β inhibitors.

Main Results:

• Several TGF-β inhibitors are approved or in clinical trials for various diseases.
• TGF-β inhibitors demonstrate significant potential in treating tumors, fibrosis, and promoting scar repair.
• Recent research has identified novel inhibitors with promising therapeutic profiles.

Conclusions:

• TGF-β inhibitors represent a significant therapeutic strategy for a range of diseases.
• Targeting TGF-β signaling offers a promising avenue for cancer treatment and managing fibrotic conditions.
• Continued research into novel TGF-β inhibitors is essential for expanding their clinical utility.